{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:57:57Z","timestamp":1790013477932,"version":"4.0.1"},"reference-count":43,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia Open"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Onchocerciasis, commonly known as river blindness, is a neglected tropical disease caused by the parasite <jats:italic>Onchocerca volvulus<\/jats:italic>. It can lead to blindness and visual impairment. Studies have also demonstrated a link between onchocerciasis and epilepsy, with there being a correlation between onchocerciasis endemicity and epilepsy prevalence. Onchocerciasis\u2010associated epilepsy (OAE) emerges predominantly in individuals aged 3\u201318, with a notable prevalence in regions where onchocerciasis transmission persists. These areas exhibit elevated rates of epilepsy, underscoring the significant impact of ongoing onchocerciasis on the incidence of epilepsy, particularly within the specified age range. Both epilepsy prevalence and incidence have evolved over the past three decades in a Tanzanian area endemic for onchocerciasis. Researchers have studied the effects of the antiparasitic drug ivermectin on OAE. About one third of Ugandan patients saw reduced seizure frequency or intensity after one 150\u2009\u03bcg\/kg dose. Clinical research in the Congo among infected epileptics on anti\u2010seizure medications (ASMs) suggested ivermectin may decrease seizure frequency following oral administration of ivermectin tablets (3\u2009mg). Beyond its antiparasitic properties, ivermectin has demonstrated anticonvulsant effects against clonic and tonic\u2013clonic seizures, likely through modulation of GABA<jats:sub>A<\/jats:sub> receptor and neuroinflammation. There is evidence of synergistic effects when combined with GABAergic ASMs like diazepam. As neuroinflammation plays a key role in OAE, ivermectin's anti\u2010inflammatory properties by inhibiting cytokines like TNF\u2010\u03b1 and IL\u20101\u03b2 are also relevant. While certain other antiparasitic drugs can interact with ASMs and have side effects like seizures, no such interactions or side effects have been reported for ivermectin. However, there is a need for more randomized controlled trials specifically evaluating ivermectin's impact on seizures in <jats:italic>O. volvulus<\/jats:italic>\u2010infected epileptics on ASMs. Given its efficacy against parasites, limited side effects, and potential anticonvulsant mechanisms, ivermectin could be a favorable first\u2010line treatment option, but further research is warranted to confirm benefits for OAE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Plain Language Summary<\/jats:title><jats:p>This article explores the potential benefits of ivermectin, a drug commonly used to treat parasitic infections, for reducing seizures in people with epilepsy linked to onchocerciasis, also known as river blindness. Research shows that ivermectin not only targets the parasitic cause of the disease but may also help reduce brain inflammation, which plays a key role in epilepsy. While early results are promising, more research is needed to confirm whether ivermectin can be a reliable treatment for epilepsy in people affected by this condition.<\/jats:p><\/jats:sec>","DOI":"10.1002\/epi4.13107","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T16:38:41Z","timestamp":1732552721000},"page":"361-367","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ivermectin as a promising therapeutic option for onchocerciasis\u2010associated epilepsy"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-9063","authenticated-orcid":false,"given":"Mohammad Amin","family":"Manavi","sequence":"first","affiliation":[{"name":"Experimental Medicine Research Center Tehran University of Medical Sciences  Tehran Iran"},{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razieh","family":"Mohammad Jafari","sequence":"additional","affiliation":[{"name":"Experimental Medicine Research Center Tehran University of Medical Sciences  Tehran Iran"},{"name":"Department of Pharmacology, School of Medicine Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Shafaroodi","sequence":"additional","affiliation":[{"name":"Experimental Medicine Research Center Tehran University of Medical Sciences  Tehran Iran"},{"name":"Department of Pharmacology, School of Medicine Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Sharifzadeh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-5565","authenticated-orcid":false,"given":"Ahmad Reza","family":"Dehpour","sequence":"additional","affiliation":[{"name":"Experimental Medicine Research Center Tehran University of Medical Sciences  Tehran Iran"},{"name":"Department of Pharmacology, School of Medicine Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"issue":"4","key":"e_1_2_10_2_1","first-page":"389","article-title":"Human onchocerciasis in Africa","volume":"57","author":"Boussinesq M","year":"1997","journal-title":"Med Trop (Mars)"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006904"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1163367"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/09286580591005787"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007407"},{"issue":"2","key":"e_1_2_10_7_1","first-page":"116","article-title":"Onchocerciasis and epilepsy","volume":"22","author":"Preux PM","year":"2010","journal-title":"Epilepsies"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000461"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2022.11.010"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37537"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30713-8"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2017.11.009"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017188"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2020.1164"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10030310"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e11375"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-024-04061-3"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10010021"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012470"},{"issue":"2","key":"e_1_2_10_20_1","first-page":"87","article-title":"The avermectins: a new family of antiparasitic agents","volume":"53","author":"Hotson IK","year":"1982","journal-title":"J S Afr Vet Assoc"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00184a014"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.8.844"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202000011"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.932711"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-023-01290-8"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-022-03804-9"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01025-4"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-07258-x"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2020.09.010"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-023-01829-y"},{"issue":"3","key":"e_1_2_10_31_1","first-page":"225","article-title":"Evaluation of ivermectin and vitamin E based combination with antiseizure rufinamide drug for mitigation of pentylenetetrazole\u2010induced kindling, behavioral challenges and histopathological aberrations","volume":"75","author":"Sabir A","year":"2024","journal-title":"J Physiol Pharmacol"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17511"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007966"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92329-E"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011662"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012059"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50582-9"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02529.x"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200317080-00003"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B2200385"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2021.133087"},{"issue":"11","key":"e_1_2_10_42_1","first-page":"1272","article-title":"Synthesis and evaluation of the effects of solid lipid nanoparticles of ivermectin and ivermectin on cuprizone\u2010induced demyelination via targeting the TRPA1\/NF\u2010kB\/GFAP signaling pathway","volume":"26","author":"Noori T","year":"2023","journal-title":"Iran J Basic Med Sci"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.11.86"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2011.135"}],"container-title":["Epilepsia Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epi4.13107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T09:14:36Z","timestamp":1738919676000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epi4.13107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/epi4.13107"],"URL":"https:\/\/doi.org\/10.1002\/epi4.13107","archive":["Portico"],"relation":{},"ISSN":["2470-9239","2470-9239"],"issn-type":[{"value":"2470-9239","type":"print"},{"value":"2470-9239","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"2024-06-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}